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The burden of 14 hr-HPV genotypes 
in women attending routine 
cervical cancer screening in 20 
states of Mexico: a cross-sectional 
study
Abraham Campos-Romero  1, Karen s. Anderson2,3, Adhemar Longatto-Filho4,5,6,7, 
Marco A. Luna-Ruiz Esparza1, David J. Morán-Portela8,9, Javier A. Castro-Menéndez8,9, 
José L. Moreno-Camacho8,9, Diana Y. Calva-Espinosa9, Manuel A. Acosta-Alfaro10, 
Freddy A. Meynard-Mejía11, Marlene Muñoz-Gaitán11 & Jonathan Alcántar-Fernández  1
In Mexico, HPV vaccines available immunize against genotypes 16/18 and 16/18/6/11; however, 
there is limited surveillance about carcinogenic subtypes in different states of the country that allow 
evaluating the effectiveness of vaccination and cervical cancer screening programs. Here, we report the 
regional and age-specific prevalence of 14 hr-HPV genotypes as well as their prevalence in abnormal 
cytology (from ASCUS to cervical cancer) among Mexican women which were undergoing from cervical 
cancer screening in the Salud Digna clinics in 20 states of the country. This study includes women with 
social security from the majority of public health institutions (IMSS, ISSSTE, SEMAR, and PEMEX), 
and women without social security. For cervical cancer screening, we used the SurePath liquid-based 
cytology and the BD Onclarity HPV Assay. From December 1, 2016, to August 2, 2018, the hr-HPV 
prevalence among 60,135 women was 24.78%, the most prevalent types were HPV 16 (4.13%), HPV 
31 (4.12%) and HPV 51 (3.39%), while HPV 18 (1.70%) was less prevalent among infected women. 
Interestingly, the genotypes not covered by current vaccines in Mexico were commonly found in 
precancerous lesions, evidencing their carcinogenic potential, so it is necessary to increase their 
surveillance and inclusion in cervical cancer screening triage.
The human papillomavirus (HPV) is the leading cause of cervical cancer and recently, has increased the evidence 
that relates HPV infections with anogenital, head, and neck cancers1. Carcinogenic types include predominantly, 
alpha 9 (HPV 16/31/33/35/52/58), alpha 7 (HPV 18/39/45/59/68), alpha 6 (HPV 56/66), and alpha 5 (HPV 51) 
genus2–4. These families differ in their mucotropisms, for example, members of alpha 7 genus have been associated 
with glandular lesions and adenocarcinoma of the cervix; meanwhile, alpha 9 genus has been found in squamous 
intraepithelial lesions and squamous cell carcinoma5,6.
Variability and prevalence of alpha members among populations would have an epidemiological impact in 
the incidence of some types of cancer. So that, screening programs, as well as preventive vaccination, have to 
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be implemented in each population to reduce the burden of HPV-related cancers. Vaccination has reduced the 
abnormal cytology rate7, as well as screening programs had contributed to the reduction of cervical cancer mor-
tality8,9; it might expect that together vaccination and screening contributes to reducing most cervical cancers.
The study of HPV genotypes allows identifying oncogenic strains present in human populations; since it has 
been reported that its prevalence and distribution vary according to countries and continents10. This differences 
in genotypes distribution may affect the effectiveness of the HPV vaccines in different populations. Regional data 
on the prevalence and distribution of HPV are essential for estimating the impact of vaccines and cervical cancer 
screening program (CCSP) in each country.
In Mexico, two previous population-based studies showed the usefulness of the HPV DNA test in CCSP11,12; 
this information has contributed to changing cancer screening from cytology to HPV triage. Regarding HPV 
prevalence, different works had been carried out in some states of the country (Supplementary Table S1); the 
majority analyzed women with social security. However, HPV infections in women without social security in 
Mexico has not been addressed.
Additionally, a detailed study of the distribution of HPV genotypes in the country is not available, which 
makes it difficult to select suitable vaccines according to the subtypes profile in the country. Despite that, in 2011, 
the Ministry of Health in Mexico approved the introduction of two prophylactic vaccines against HPV16/18 and 
HPV6/11/16/18 into the national vaccination program to prevent cervical cancer13. These vaccines were selected 
by the growing evidence of the carcinogenic potential of HPV16/18, which has been found in more than 70% of 
cervical cancer cases globally14.
However, it might be that the diversity of alpha members would impact vaccination effectiveness since the 
available vaccines in the market, not cover all potentially carcinogenic subtypes. For that reason, it is essential 
the surveillance of HPV genotypes, to collect clinical and epidemiology information that allows to evaluate the 
effectiveness of vaccination programs and help in the selection of suitable vaccines in each country.
In this study, we investigate the prevalence and distribution of circulating high risk-HPV genotypes (hr-HPV) 
in 60,135 women (including women with or without social security) from 20 states of Mexico. Also, we identified 
the most common genotypes present in precancerous lesions. This study, together with previous works can serve 
as a reference to guide cervical cancer screening and HPV vaccination programs in Mexico.
Material and Methods
Salud Digna is a private not for profit and non-government institution which provides diagnostic services in 
Mexico through outpatient diagnostic clinics located in 20 of 32 states of the country, in which could are atten-
dant all people, no matter their socio-economic status, or if they have social security or not.
Study design and population. For this retrospective cross-sectional study, we analyzed anonymized elec-
tronic health records of cervical cancer screening from patients whose where attendant in the outpatient care 
clinics Salud Digna in 20 states of Mexico from December 01, 2016 and 02 August 2018. We include all available 
data collected during gynecological examinations, including data on demographics, gynecologic, and obstetric 
information. A unique standardized and validated survey was applied for data collection in all clinics. The cases 
included were from adult women (18 to 90 years), which were screened for cervical cancer. The exclusion criteria 
were the following: women younger than 18 years, pregnant women, and women with hysterectomy. For geo-
graphical analysis, we included states with 140 or more subjects. This threshold was considered from the sample 
size calculations for cross-sectional studies15; in this case, for an expected HPV-infections prevalence of 10% 
based on the mean of prevalence reported by population-based studies in Mexico12,16,17.
Consent for using information, handling data and protecting information privacy. The consent 
for the use of information from health records was obtained according to the Mexican Federal Law on Personal 
Data Protection (LFPDPPP, by its acronyms in Spanish). People who are attendant in the Salud Digna clinics 
accept our privacy policy which includes the use of their information for scientific research purposes; by the 
above, we do not need specific informed consent from each people included in this work, because this study is a 
cross-sectional analysis of an electronic health registry. We handled data protection and privacy of its, according 
to national laws and guidelines in Mexico. Data obtained was anonymized by the assignation of a unique ID code 
to protect the identity of people and to prevent data duplication in subsequent analysis. Aggregation of informa-
tion was used to enhance data protection.
Ethical statement. This study was approved by the Ethical Review and Research Board of Salud Digna. All meth-
ods were carried out by the approved guidelines and the Declaration of Helsinki.
Procedures. The procedures for the Pap test and HPV genotyping used to generate the information collected in 
the electronic health records used in this study are described below. Cervical cancer screening results from the 
registry were obtained from the samples collected in the BD SurePath liquid-based cytology collectors during 
gynecological examinations in each clinic, then, were processed in the Cytology unit, and Molecular biology lab-
oratory at the National Reference Center of Salud Digna in Culiacan, Sinaloa. Cytology samples were processed 
into the BD Totalys MultiProcessor (BD Diagnostics, Sparks, USA) for the cell enrichment of cervical samples 
(automated sample transfer, cells centrifugation, liquid decanting, and cells aspiration) as well as to make aliquots 
for an HPV test.
The slides preparation and staining for Pap smears were performed into the BD Totalys SlidePrep (BD 
Diagnostics, Sparks, USA) according to the manufacturer´s recommendations. Slides were visually inspected 
in Carl Zeiss Primo Star HD microscopes (Carl Zeiss Microscopy, LLC, USA) by 13 certified cytotechnolo-
gists; all abnormalities observed were confirmed for certified pathologists and 14% of total slides inspected by 
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cytotechnologists were re-analyzed by independent pathologists (Pathologists were blinded for the commentar-
ies of cytotechnologist). Pap test was performed according to the 3rd ed. of The Bethesda System for Reporting 
Cervical Cytology18.
The HPV DNA testing was performed using the automated workflow on the Viper LT system. HPV type was 
determined using the real-time PCR BD Onclarity HPV Assay (BD Diagnostics, Sparks, USA) which detects and 
amplify HPV type-specific E6 and E7 genes19. This assay simultaneously detects 14 high-risk HPV types, in three 
different reactions. R1 detects individually HPV 16/18/45, R2 detects individually HPV 31 and two groups: G1 
(HPV 33/58), and G2 (HPV 56/59/66); R3 detects individually HPV 51/52 and G3 (HPV 35/39/68); all reactions 
use the human β-globin gene as an internal control.
Statistical analysis. Descriptive statistics were performed on all data sets. For categorical data, the Wilson 
score method without continuity correction was performed to calculate 95% CI. Genotypes detected in the G1, 
G2, and G3 had regarded as a single unit for results descriptions. We evaluated the associations between demo-
graphic, gynecobstetrics, and other factors to HPV infections using a stepwise multivariable logistic regression 
model. All variables significantly associated in the univariable analysis (p < 0.05) were selected for inclusion in 
the multivariate logistic regression model, which was used to control for potentially confounding factors. The 
adjusted odds ratio (OR) were calculated from age-adjusted multivariate logistic regression. To analyze the onco-
genicity of HPV genotypes, we used registries from women undergoing both tests (HPV and Pap test); odds ratio 
(OR) of each genotype were calculated from the univariate logistic regression model. The analyses were done in 
SPSS V. 24 (IBM, USA).
Results
Characteristics of the population. Between December 01, 2016 and 02 August 2018, 60,328 women were 
attendant for cervical cancer screening in outpatient diagnostic clinics Salud Digna located in 20 of 32 states 
of the country. 5 registries (belonging women younger than 18 years) were excluded from the dataset; also 188 
registries were excluded because they belong from states with less than 140 women screened. For the HPV prev-
alence as well as geographical and age-specific analysis, 60,135 registries were included. For risk factors analysis 
and the relationship of HPV genotypes according to cytology results, 52,415 registries were included, and 7,721 
registries with incomplete gynecological and clinical information were excluded (in each analysis missed values 
and exclusions are declared).
In this study, women from 18 to 88 years were screened for cervical cancer; the mean age was 38.76 years; 
53.69% of women had their first sexual intercourse at 18 years or older. Also, the majority of women declared 
not to use tobacco (75.59%). Most of the women studied have been pregnant (71.64%), 51.34% declared to used 
contraceptive methods, from these, 21.74% corresponding to condom use; 70.72% of women previously have 
been undergoing to Pap test. It is important to note that most of the women declared not having social security 
(70.81%). A summary of the demographic characteristics of women included in this study is shown in Table 1.
Prevalence of circulating hr-HPV genotypes. The prevalence of hr-HPV in 60,135 women was 24.78% 
(Fig. 1); the most prevalent genotypes were HPV 16 (4.13%), HPV 31 (4.12%), and HPV 51 (3.39%), while HPV 
18 was less prevalent (1.70%) (Table 2). From the genotypes detected in groups, G2 (HPV 56/59/66) was the most 
prevalent (9.05%), followed by G3 (HPV 35/39/68) with 5.59% (Table 2). Moreover, women without social secu-
rity had a higher prevalence of infections (25.72%) than women with social security (22.48%) (Supplementary 
Table S2). In contrast, no significant differences were observed in the prevalence of hr-HPV genotypes between 
women with or without social security and between women belonging to different public health institutions 
(Supplementary Table S3).
Prevalence of HPV genotypes in 20 states of Mexico. In this work, we include those states in which 
the number of records (sample size for these states) was at least 140. This threshold was considered from the sam-
ple size calculations for cross-sectional studies15. The expected HPV prevalence was 10% based on the mean of 
prevalence previously reported by population-based studies in Mexico12,16,17. Among states analyzed, Chihuahua 
(28.74%), and Nayarit (28.33%) had the highest prevalence of infections, while in Quintana Roo (21.17%) and 
Sinaloa (21.54%) we found the lowest prevalence (Fig. 1). An age-standardized rate is shown in Supplementary 
Table S4. According to genotype, the HPV 16 was more prevalent in Sonora (5.70%), and Chihuahua (5.59%); 
meanwhile the lowest prevalence was found in Puebla (3.17%), and Sinaloa (3.42%).
We found that the HPV 31 was more prevalent in San Luis Potosi (6.07%) and Aguascalientes (5.20%); while 
the lowest prevalence was observed in Quintana Roo (1.95%), and Sinaloa (3.01%). The HPV 51 was more fre-
quent in Nayarit (4.78%), and Nuevo Leon (4.39%), in contrast, we observed the lower prevalence in Quintana 
Roo (2.43%), and Durango (2.45%). The HPV 52 was most prevalent in Chihuahua (4.68%) and Veracruz 
(4.63%); in contrast in Sinaloa (2.84%), and Nuevo León (2.93%) it was observed the lowest frequencies (Table 2).
The HPV 18 was more prevalent in Nayarit (2.85%) and Nuevo Leon (2.66%) than in Quintana Roo (0.97%), 
and Durango (1.15%) in which was less prevalent. In Chihuahua (3.60%) and Nayarit (2.26%), HPV 45 was the 
most prevalent; meanwhile in Quintana Roo (0.73%), and Durango (1.15%) was less prevalent. The G2 (HPV 
56/59/66) was more prevalent in Nuevo Leon (11.32%), and San Luis Potosi (10.90%), and less frequent in 
Quintana Roo (6.81%) and Sinaloa (7.44%). The G3 (HPV 35/39/68) was more prevalent in Veracruz (7.48%), 
and Chihuahua (6.85%), while in Guanajuato (4.83%), and Coahuila (4.86%) was less prevalent. Finally, the G1 
(HPV 33/58) was more prevalent in Chiapas (4.86%), and Michoacan (4.37%), and less prevalent in Quintana 
Roo (2.19%), and Nuevo Leon (2.40%) (Table 2).
Age-distribution of hr-HPV genotypes. The age-prevalence of HPV infections is shown in Fig. 1C; 
the higher prevalence was observed in women younger than 25 years (47.79%) and subsequently, infections 
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decreases; the second peak of infections was observed in women older than 70 years (12.79%). A similar trend 
was observed in all HPV types. For example, HPV 45 reaches their higher prevalence in women with 20 to 30 
years; only HPV 16/52/18, G2 (HPV 56/59/66) and G3 (HPV 35/39/68) were present in women older than 70 
years (Supplementary Fig. S1).
Association between selected risk factors to hr-HPV infections. Moreover, we assessed the rela-
tionships between gynecologic, obstetrics, and lifestyle characteristics for HPV infections. We found that women 
without social security showed an increased the odds to get infected (OR = 1.10; 95%CI = 1.05–1.16). Similarly, 
sexual intercourse before 18 years was significantly associated (OR = 1.15; 95%CI = 1.10–1.20). However, 
Characteristic Number of people %
Age (years)















Type of contraceptive method used
  Condom 6,713 21.74
  Intrauterine device (IUD) 3,766 12.20
  Hormonal* 4,124 13.36
  Bilateral tubal occlusion 15,790 51.15




















Type of social security
  IMSS 9,756 55.57
  ISSSTE 2,588 14.74
  SEMAR & PEMEX 183 1.04
  Seguro popular 5,028 28.64
Table 1. Demographic characteristics of 60,135 women included in this study. *Includes oral contraceptives, 
injections and implants.
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menarche age lower than 12 years did not show a significant association with HPV infections (OR = 0.97; 
95%CI = 0.92–1.01) (Table 3).
Furthermore, we found that women that never had been pregnant showed increasing odds to be infected 
(OR = 1.84; 95%CI = 1.66–2.02) than women with a history of pregnancies. In this way, women who have had 
more than one pregnancy showed an odds reduction to get infected. Regarding birth types, the cesarean surgeries 
reduced the odds of infections (OR = 0.86; 95%CI = 0.82–0.90); however, births were not related (OR = 1.03; 
95%CI = 0.98–1.08). Women with a history of abortions slightly increased their odds (OR = 1.09; 95%CI = 1.04–
1.15) (Table 3).
The tobacco consumption (OR = 1.24; 95%CI = 1.17–1.31) as well as sexually transmitted diseases (STD) 
were significantly associated to HPV infections (OR = 1.21; 95%CI = 1.09–1.34). Of the STD’s, infections with 
Trichomonas vaginalis (OR = 1.52; 95%CI = 1.29–1.78), Candida (OR = 1.12; 95%CI = 1.04–1.21) or Gardnerella 
vaginalis (OR = 1.51; 95%CI = 1.41–1.61) showed significant odds (Table 3).
Association between cervical cytology and HPV genotypes. We analyzed the prevalence of hr-HPV 
according to cytological results in women undergoing co-testing procedures (Pap test and HPV typing at the 
same time). We found that the prevalence of hr-HPV was 21.21% in women negative for intraepithelial lesions 
or malignancy (NILM), 73.04% in atypical squamous cells with undetermined significance (ASCUS), 82.14% in 
atypical squamous cells cannot exclude high-grade squamous intraepithelial lesions (ASC-H), 73.68% in atypical 
glandular cells (AGC), 84.09% in low-grade squamous intraepithelial lesions (LSIL), 92.22% in high-grade squa-
mous intraepithelial lesions (HSIL), and 78.57% in cervical cancer cases (Table 4).
The most prevalent genotypes from NILM to HSIL were HPV 16 (NILM: 3.21%, HSIL: 48.88%), HPV 31 
(NILM: 3.48%, HSIL: 13.33%), HPV 51 (NILM: 2.69%, HSIL: 5.55%) and HPV 52 (NILM: 2.75%, HSIL: 7.77%). 
In the cervical cancer cases, HPV 16 (42.86%) and HPV 31 (21.43%) were the most prevalent genotypes (Table 4). 
Regarding genotypes detected in groups, they were more prevalent in abnormal cytology and HSIL, but low prev-
alent among cervical cancer (Table 4).
The analysis by HPV genus showed that members of the alpha 9 genus, (e.g., HPV 16/31 and HPV 33/58) 
were more prevalent in all cytological abnormalities including cervical cancer; while the alpha 7 genus (e.g., 
HPV 18/45, and HPV 39/59/68) were less frequent among cytological abnormalities and cervical cancer. Despite 
that genotypes of the alpha 6 genus (e.g., HPV 56/66) were the most prevalent in all categories of the cytology 
test; these genotypes were not associated with precancerous lesions and cervical cancer. Similarly, HPV 51 (from 
alpha 5 genus) was not significantly associated with precancerous lesions and was absent in cervical cancer cases 
(Table 4).
Discussion
This study is the first in Mexico that comprises a wide geographical dispersion, including 20 of 32 states of the 
country. In this work, we show the prevalence of carcinogenic HPV types among Mexican women undergoing 
cervical cancer screening in private outpatient care Salud Digna clinics. The study population consisted of gyne-
cological outpatients and asymptomatic women; some of them are affiliated to public health institutions (such as 
IMSS, ISSSTE, PEMEX, SEDENA, and Seguro Popular), and others do not have social security (Table 1).
The prevalence of 14 hr-HPV in 60,135 women was 24.78%. Previous studies in Mexico in different health 
care institutions reported prevalences of 10–49.7%, which includes low and high-risk HPV types. There are some 
differences between previous works and this study that limits the comparison of the results, including the type 
Figure 1. Prevalence of hr-HPV infections in 60,135 women from 20 states of Mexico. Coropletic histogram 
(A) and map (B) shows the prevalence of hr-HPV infections in 20 states of Mexico. The color red indicates the 
states with the highest prevalence of infections, while yellow shows the states with the lowest prevalence. Gray 
color (in the map) shows the states that are not included in this work. (C) The 5-year prevalence of hr-HPV 
infections in 60,135 women screened in 20 states of Mexico, the trend of age-specific prevalence was evaluated 
with the chi-squared (χ2) test for trend. The confidence intervals of the prevalence in each state are shown in 
Table 2.
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and design of the study, and the intrinsic limitations of HPV test used in each work which has been further dis-
cussed20,21; the above can be reviewed in detail in the Supplementary Table S1.
One of the main differences is that we used the real-time PCR Onclarity HPV assay test for HPV typing which 
has been recently approved by the Food and Drug Administration (FDA) agency in the US for HPV test22. This 
assay detects 13 carcinogenic HPV types and 1 possible carcinogenic (HPV 66)23. Six genotypes are detected indi-
vidually (16, 18, 31, 45, 51, and 52) and the others are detected in groups: G1 (HPV 33/58), G2 (HPV 56/59/66), 
and G3 (HPV 35/39/68), reducing the possibility of knowing the real prevalence of each genotype, representing 
a limitation for HPV genotypes surveillance, but not for clinical purposes22. The G2 and G3 groups have a lower 
risk of cervical lesions (among carcinogenic types) compared to HPV 16 according to globally reports10,14,23,24.
Moreover, this test targeting HPV DNA E6 and E7 genes, this implies that those infections in which the L1 
gene has been lost by viral integration can be detected because the E6 and E7 genes are not affected by this event21; 
in contrast, L1-based typing tests could miss HPV infections in cervical samples. Also, a comparison between 
consensus PCR targeting L1 primers (MY09/11) and type-specific E6/E7 HPV PCR showed that L1 PCR failed to 
detect 10.9% of HPV infections25, also MY09/11 showed lower sensitivity (87.9% vs 98.3%) and specificity (38.7% 
vs 76.14%) than type-specific E6/E7 primers25. Another primer set is GP5+/GP6+, which also targeting L1 and 
has similar sensitivity than MY09/1126. However, this primer set to fail in the amplification of DNA from multiple 
HPV present in a single sample26. The above might explain why we observed a high prevalence of HPV infections 
using E6/E7-based typing test than previous works in the country that used L1-based typing tests (Supplementary 
Table S1) which might do not detect HPV infections correctly.
States n
Prevalence of HPV infections % (95% CI)



















































































































































































































































































































































































































Table 2. Prevalence of circulating HPV genotypes in 60,135 women from 20 states of Mexico. Abbreviatures: 
CI = Confidence interval, HPV = Human papillomavirus, G1 = HPV 33/58, G2 = HPV 56/59/66, G3 = HPV 
35/39/68.
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Furthermore, studies of HPV in women without social security in Mexico are limited. In this work, 70.81% of 
women studied had no social security, in which the prevalence of hr-HPV infections was higher (25.72%) than 
women with social security (22.48%) affiliated to the majority of public health institutions of the country (IMSS, 
ISSSTE, Seguro Popular, SEDENA, and PEMEX). Also, the age-distribution of HPV infections observed in this 
study was similar to previous studies in Mexico11,16,17,27 and other Latin-American countries10.
In this work, we found that women without social security increase their odds of getting HPV infections. The 







(95% CI) P value
Social security
   Yes 15,926 22.11 1
   No 36,488 25.00 1.10 (1.05–1.16) <0.0001
Age at menarche (years)
   ≥12 40,428 23.75 1
   <12 11,986 25.38 0.97 (0.92–1·01) 0.154
Age at first sexual intercourse (years)
   ≥18 32,288 21.79 1
   <18 20,126 27.86 1.15 (1.10–1.20) <0.0001
History of pregnancies
   Yes 43,081 21.10 1
   No 9,333 38.08 1.84 (1.66–2.02) <0.0001
Number of pregnancies†
   1 8,044 30.30 1
   2–3 23,230 19.81 0.82 (0.77–0.88) <0.0001
   >3 11,807 17.38 0.89 (0.82–0.96) <0.0001
History of Parity†
   No 16,436 22.66 1
   Yes 26,645 20.14 1.03 (0.98–1.08) 0.196
History of cesarean surgeries†
   No 21,459 22.45 1
   Yes 21,622 19.76 0.86 (0.82–0.90) <0.0001
History of abortions†
   No 28,537 20.74 1
   Yes 14,544 21.80 1.09 (1.04–1.15) 0.005
Tobacco consumption
   Never 45,464 23.01 1
   Current 6,950 31.42 1.24 (1.17–1.31) <0.0001
Sexually transmitted diseases
   No 50,384 24.01 1
   Current 2,030 27.00 1.21 (1.09–1.34) <0.0001
Current infection with Trichomonas vaginalis
   No 51,665 24.00 1
   Yes 749 32.71 1.52 (1.29–1.78) <0.0001
Current infection with Candida
   No 48,508 23.77 1
   Yes 3,906 28.55 1.12 (1.04–1.21) 0.004
Current infection with Gardnerella vaginalis
   No 47,179 23.07 1
   Yes 5,235 33.60 1.51 (1.41–1.61) <0.0001
Table 3. Correlations between gynecologic, obstetrics and lifestyle characteristics with HPV infections in 
women screened in 20 states of Mexico. Odds ratio (OR) were adjusted by age (included in the model as a 
categorical variable; <25, 25–34, 35–44, 45–54, 55–64, 65+). The variables included in the model were the 
following: social security, age at menarche, age at first sexual intercourse, use of contraceptive method, previous 
pap test, history of pregnancies, number of pregnancies, history of parity, history of cesarean surgeries, history 
of abortions, number of abortions, tobacco consumption, sexually transmitted diseases, infections with 
Trichomonas vaginalis, Candida, Gardnerella vaginalis and Herpes virus. Abbreviatures: CI = Confidence 
interval. HPV = Human papillomavirus. †Nulliparous women were excluded, ‡Nulliparous women and women 
without a history of abortions were excluded. Odds ratio were obtained from stepwise multilevel logistic 
regression equations in 52,414 women with complete data for all covariates.
8Scientific RepoRts |         (2019) 9:10094  | https://doi.org/10.1038/s41598-019-46543-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
Additionally, sexually transmitted diseases were highly related to HPV infections which had been reported in 
other populations28–30. Interestingly, multiple pregnancies were associated with a reduction in the odds of infec-
tions. Also, cesarean surgeries and abortions were weakly associated with HPV infections. The information about 
lifetime-sexual partners is an important risk factor for HPV infection; however, we could not get that information 
during interviews for cervical cancer screening, which could confuse some of the factors studied here.
Regarding the prevalence of HPV genotypes, we found that HPV 16, 31 and 51 were the most prevalent, 
also G2 (HPV 56/59/66), G3 (HPV 35/39/68) were the commonest, while HPV 18 was less prevalent, which 
differs with the majority of previous reports in the country (Supplementary Table S1). In Mexico, the National 
Immunization Council in 2011 approved the nationwide expansion of school-based HPV vaccination program 
which includes all girls aged 9 years and unschooled girls aged 11 years13; this program used vaccines against HPV 
16/18 and HPV 6/11/16/18.
The first generation of women vaccinated in 2011 has reached the age of 18–20 years; this age group represents 
12.08% of the women studied in this work so that we expect that in our work the majority of women are not vacci-
nated (87.92%). In consequence, we consider that the low prevalence of HPV 18 observed would be explained by 
different factors such as mucotropism of HPV genotypes5,6, and ethnicity31–33 rather than vaccination.
Additionally, we found a difference in the prevalence of hr-HPV genotypes between young and old women 
(see Supplementary Fig. S1); despite the low prevalence observed in old women, the genotypes observed in this 
age group had been associated with cervical cancer34–36, this might explain the raising of cancer cases in old 
women in the country37. Furthermore, we found that the most prevalent genotypes from normal to abnormal 
cytology were HPV 16/31/51, which was similar to previous reports in women with normal cytology10,35,36,38 and 
cervical cancer cases14,24,36,39. However, HPV 18 and 45 were less frequent in this population. In contrast, geno-
types detected in groups (56/59/66 and 35/39/68) were commonly found in normal cytology and LSIL, but lower 
in HSIL and CC cases, showing a lower risk for high-grade cervical lesion promoted by this genotypes; which is 
consistent with worldwide reports14,24.
One of the limitations of this work is the low number of cancer cases reported and the lack of information 
about colposcopy and biopsy results since this work studied an ambulatory population, women that need a col-
poscopy were referred to other health institutions and specialized hospitals. For the above is not possible to assess 
the contribution of HPV types in cervical cancer as well as to evaluate the impact of vaccination in the reduction 
of cervical cancer.
It is important to know that we found a high prevalence of HPV 31 and HPV 33/58 in normal and abnormal 
cytology; a previous work found that these genotypes had a comparable risk for HSIL development that of HPV 
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Table 4. Prevalence of hr-HPV genotypes according to cytological results. Abbreviatures: NILM: Negative for 
intraepithelial lesion or malignancy; ASCUS: Atypical squamous cells with undetermined significance; ASC-H: 
atypical squamous cells cannot exclude high-grade squamous intraepithelial lesions; AGC: atypical glandular 
cells; LSIL: low-grade squamous intraepithelial lesion; HSIL: high-grade squamous intraepithelial lesion; CC: 
cervical cancer; P (%): prevalence; CI: Confidence interval; HPV: Human papillomavirus; G1: HPV 33/58; G2: 
HPV 56/59/66; G3: HPV 35/39/68.
9Scientific RepoRts |         (2019) 9:10094  | https://doi.org/10.1038/s41598-019-46543-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
1840. However, these genotypes are not included in the current vaccines available in the country (Cevarix and 
Gardasil4). Recently, a nine-valent vaccine (Gardasil9) which immunizes against HPV 6/11/16/18/31/33/45/52/58 
has been tested to assess their safety and efficacy to reduce precancerous lesions41–43 and has been approved for 
use in Europe, Canada, Australia, and the US44. This vaccine immunizes against the most prevalent carcinogenic 
genotypes found in this work and other previous studies in the country, so that could be suitable for vaccination 
in Mexico.
Moreover, with the development and validation of HPV tests, different screening algorithms for cervical can-
cer had been proposed45, including HPV 16/18 typing to refers women to colposcopy45–49. In Mexico, the HPV 
triage coupled to hr-HPV 16/18 genotyping shown a good cost-effectiveness relationship than hr-HPV plus pap 
test50. A recent analysis showed that HPV 31/33 have higher positive predictive values for CIN3 and CIN2 than 
HPV 1851. Taking into account the results shows here, and the previous works in the country, we consider that the 
inclusion of HPV 31 in the HPV typing triage in Mexico would improve cervical cancer screening due to the high 
prevalence of this genotype among cervical neoplasias.
The information showed in this work does not represent the Mexican population entirely; however, this is 
one of the first approaches to known the circulating hr-HPV genotypes in Mexico. Our results show a growing 
prevalence of HPV genotypes not included in the current vaccines applied in the country. Together all work on 
HPV in Mexico in women from different regions of the country, with or without social security and with different 
population profiles provides valuable information that will help to guide the future cervical cancer screening pro-
grams and HPV vaccination in Mexico. Also, it is necessary to extend and continue the surveillance of circulating 
HPV genotypes to evaluate the effectiveness of vaccination and screening programs to reduce of cervical cancer 
and other HPV related cancers in Mexico in the coming years and long-term.
Data Availability
All relevant data concerning this work are published in this article and in the supplementary material.
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